Silence Therapeutics plc SEC filings SLNCF
Silence Therapeutics plc has 275 filings in SEC EDGAR's recent list, going back to Jan 5, 2010. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (material agreement, regulation fd disclosure).
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 19, 2026 | — |
| DEFA14A | Additional proxy material | Oct 19, 2026 | — |
| DEF 14A | Proxy statement | Apr 29, 2026 | Jun 16, 2026 |
| DEF 14A | Proxy statement | May 16, 2025 | Jun 26, 2025 |
| PRE 14A | Preliminary proxy statement | May 6, 2025 | Jun 26, 2025 |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SLN (Nasdaq), SLNCF (OTC)
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1479615
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.